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Abstract
In the recent years, it has become clear that septic shock is characterized by the simulta-
neous production of inflammatory and anti-inflammatory mediators; the primary role 
of the latter is to counterbalance the former, thus limiting the severity of their systemic 
effects. However, in a number of patients, the anti-inflammatory substances can cause a 
downregulation in both the innate and adaptive immune capabilities, leading a second 
phase characterized to secondary infections caused by opportunist germs and the reacti-
vation of latent viruses, muscle wasting; altogether, these abnormalities set the stage for 
a chronic critical condition. This condition, whose identification is relatively recent, is 
called immunoparalysis. Unfortunately, the current approach to septic shock is focused 
much more on the inflammatory phase than in the ensuing immunoparalysis, whose 
diagnosis can be challenging. In this chapter, the role played by both classes of mediators, 
the monitoring of the immune system, and the possible current and not yet available 
therapeutic strategies of immunoparalysis are reviewed and discussed.
Keywords: septic shock, compensatory anti-inflammatory reaction syndrome, 
immunoparalysis, immunomonitoring
1. Introduction
The classical clinical manifestations of septic shock (SS) include fever, tachycardia, arterial 
hypotension, and abnormalities of the white blood cell count (WBC) associated with a wide 
range of organ dysfunction carrying a substantial risk of death [1]; the current approach, 
issued under the auspices of the Surviving Sepsis Campaign on the basis of clinical trials ful-
filling the evidence-based medicine (EBM) criteria, includes the rapid administration of wide-
spectrum antibiotics, the maintenance of a proper perfusion pressure via the administration 
of fluids and/or to vasopressors, the drainage of septic foci, etc. [2]. Overall, it appears that 
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both the description and the therapies apply to acutely ill patients suffering from an infection-
induced overwhelming reaction determined by a huge number of pro-inflammatory media-
tors produced and released by the innate immunity system. However, more than 20 years 
ago, Bone [3] hypothesized that this early hyperinflammatory phase could be accompanied 
by a compensatory anti-inflammatory response (CARS) aiming to limit the tissue damage. 
In the last decade, the concept of CARS has changed from a time-limited and somehow ben-
eficial mechanism to a harmful reaction, potentially leading to a condition of marked reduc-
tion of the immune capabilities known as immunoparalysis [4–6]. Clinically, this condition 
is marked by recurrent and/or unresolving infections caused by germs with relatively low 
virulence; the reactivation of silent virus such as cytomegalovirus (CMV), Epstein-Barr virus 
(EBV), and herpesvirus (HV); a persisting low-grade inflammation; nutrition-resistant hyper-
catabolism; and muscle wasting [7, 8] (Table 1). The immunoparalysis characterizes also the 
clinical course of the chronic critically ill patients, namely, subjects who survived the initial 
insult (i.e., septic shock due to pneumonia, peritonitis, etc.) but fails to recover enough to be 
weaned from the mechanical ventilation and discharged from the intensive care unit (ICU) 
[9]. Moreover it should be noted that factors other than pathophysiological mechanisms can 
reduce the immune response, including the administration of steroids and norepinephrine 
[1, 10]. The aims of this chapter are (1) to review the main mechanism determining a SS, (2) 
to describe the transition from an easily recognizable hyperinflammatory condition to a less 
straightforward diagnosable one featured by a downregulation of the immune capabilities, 
(3) to provide some monitoring tools of the immune function, and, finally, (4) to identify some 
possible therapeutic approaches.
Variable Uncontrolled inflammatory response Immunoparalysis
Clinical phenotype Fever, arterial hypotension, elevated cardiac 
output, rapidly evolving MODS, community 
or surgical infections
Altered mental status, normo-/hypothermia, 
slow-evolving MODS, health care- or hospital-
acquired infections
Patients population Young, middle-aged Elderly, fragile
Comorbidities Often absent
Low Charlson’s index
Often present
High Charlson’s index
Germs characteristics Virulent, toxin releasing Low virulence, opportunistic
Latent virus reactivation
Laboratory findings ↑↑ or ↓ neutrophil count,
↑ blood lactate levels
↓ lymphocyte
Nutritional status Normal Sarcopenia/cachexia
Muscle wasting
Clinical course Resolution of sepsis
Immunorestoration
Early deaths
Protracted ICU LOS
Chronic critical disease
Late deaths
LOS, length of stay.
Table 1. Different clinical presentations of sepsis-induced immunological alterations.
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2. Pathophysiology of septic shock: a classical overview
2.1. The inflammatory response
Since the late 1970s, it has become clear that the clinical and biochemical manifestations of 
sepsis and its related complications are not caused directly by invading germ(s) but rather 
by the host’s response to the infection. The innate immune response largely accounts for the 
above described signs and symptoms. The presence of microorganism-derived substances 
collectively known as pathogen-associated molecular pattern (PAMP) which include endo-
toxin, capsular antigens, elements derived from the cell wall, flagellins, and other substances 
derived from the bacterial lysis determines the rapid activation of genes encoding for an 
extremely elevated (and still partially unknown) mediators able to trigger a strong inflam-
matory reaction, including the tumor necrosis factor-α (TNF), a number of interleukins (IL), 
the platelet-activating factor (PAF), etc. (Table 2). It is worthwhile to recall that (a) the list 
of mediators is incomplete because new elements are added on a weekly or at maximum 
monthly basis, (b) the rise of blood levels of inflammatory mediators is a matter of minutes 
since it represents the first line of defense to contrast the deleterious effects of PAMP and 
DAMPS, and (c) for this reason, the innate response is highly similar among all species of 
mammalians [6].
Independently from their biochemical structure, the term inflammasome lumps together all 
these heterogeneous mediators that are characterized by (a) the presence of many positive 
and negative feedback loops, determining an array that can be better conceived as a network 
Cytokine Source Effects Interactions Antagonists
TNF Innate and adaptive 
immune system
Activation of immune cells
Fever cachexia, apoptosis
Activation of 
downstream 
inflammatory mediators
Soluble TNF 
receptors
Anti-TNF ab
IL-1 “ Fever, pro-coagulation
Hematopoiesis
“ IL-1 receptor 
antagonists
IL-6 “ Activation of T and B 
lymphocytes
Fever
Inhibits the release of 
TNF and IL-1
Promotes anti-
inflammatory response
IL-6 receptor 
antagonists
IL-12 Monocyte, macrophages, 
neutrophils, dendritic 
cells
Activation of adaptive 
response
Promotes IFN-γ 
production
Unknown
IFN-γ NKT cells
CD 8 T cell
Antiviral action
Potentially reverse 
immunoparalysis
Released in response to 
TNF, IL-12, and IL-18
Unknown
TNF, tumor necrosis factor; IL, interleukin; IFN, interferon.
Table 2. Some relevant pro-inflammatory mediators.
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and not a cascade, thus making understandable the therapeutic failure demonstrated in many 
trials in which septic patients were treated with substances aimed to the block a single media-
tor via monoclonal or chimeric specific antibodies (Ab) such as anti-TNFαAb or with the 
administration of circulating antagonists (ra) (i.e., soluble IL1-ra and TNF TNFα-ra) directed 
to block the receptors present on the cell surface; (b) the pleiotropic and paracrine effects, 
accounting for the multiple effects exerted in different organs; (c) the interference with the 
mitochondria causing a disturbance of the O
2
 uptake and consumption by the tissues; and 
(d) the interaction with other biological systems including the complement system and the 
coagulative cascade. Notably, the very same mediators are produced in noninfectious con-
ditions, including trauma, low-flow states, surgery, burns, etc.; in these circumstances the 
trigger is represented by an intracellular substance derived from the injured tissues (DAMP, 
damage-associated molecular patterns). The endothelium is massively involved in this reac-
tion causing a microvascular plugging and the abnormal production of nitric oxide (NO) 
which exert a profound vasodilation [11, 12].
From an evolutionary perspective, it is likely that these mediators have been developed and 
maintained, aiming to contain the initial inoculum and to destroy the responsible organisms. 
This explains why in most cases an infection does not cause a SS: actually, the latter occurs only 
when the pro-inflammatory mediators exert their effects at a systemic level, thus determining 
the clinical phenotype of SS and the almost unavoidable presence of the simultaneous dys-
function of different organs and systems even not directly involved by the infection (MODS).
2.2. The compensatory reaction
The secretion of inflammasome is accompanied by the production of other substances aimed 
to limit their action at a local level and, at the same time, to prevent their systemic spread 
(Table 3). As stated above for the inflammatory mediators, their list is incomplete for the very 
same reasons. Actually, it was hypothesized that during the initial phase (almost), only pro-
inflammatory mediators were produced and that these conditions subsided due to the action 
of the CARS-associated mediators. Despite its popularity, it became clear that this scheme 
represents an oversimplification as (a) both classes of substances are produced since the ini-
tial phase of sepsis albeit in different rates; (b) the action of anti-inflammatory mediators 
is responsible for the late-onset immunoparalysis; and finally (c) a low-level production of 
pro-inflammatory substances can be maintained even during the advanced stages of sepsis 
leading to malnutrition, protein waste, and reduced adaptive immunity. Overall, the sepsis-
associated immunoparalysis resembles the normal aging process of the immune system 
(immunosenescence) that is characterized by the overall downregulation of both the innate 
and adaptive immunity functions. This appears particularly relevant as the ever-increasing 
age of septic patients exposes them to both conditions.
Put shortly, it appears that the mediators implicated in the CARS can represent a double-
edged sword, as they both can exert (a) a beneficial role when they determine the restoration 
of the immune condition existing prior to the sepsis (immune restoration) and (b) can trigger 
a life-threatening condition when their excess production and/or duration of action causes the 
shutdown of the immune response [13, 14].
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In conclusion, (at least) three clinical trajectories can be hypothesized (Figure 1): the first 
includes patients with an intense hyperinflammatory reaction that subsides once the CARS is 
well established and the immune function is restored; in the second the initial phase is shorter 
and weaker, and the CARS determines a short-lived immunoparalysis preceding the return 
Cytokine Source Effects Interactions
IL-10 Innate and adaptive 
immune system
Immunosuppression
Inhibition of antigen presentation and 
phagocytosis
Suppression of the production of 
inflammatory mediators
TGF-β Macrophages
Smooth muscle cells
Immunosuppression ”
IL-4 Mast cells
T
h
2 T cells
Basophils
Eosinophils
Promotes T
h
2 T-cell differentiation Induces the production of IL-10
TGF, transforming growth factor.
Table 3. Some relevant anti-inflammatory mediators.
Figure 1. Possible clinical trajectories of patients with sepsis shock. Line 1, intense hyperinflammatory reaction 
followed by CARS and the return to the baseline immune state. Line 2, weak hyperinflammatory reaction followed by 
immunoparalysis and immune restoration. Line 3, immunoparalysis not preceded by a hyperinflammatory reaction.
Immunoparalysis in Septic Shock Patients 5
toward the baseline immune function; and in the third one, the CARS prevails and causes the 
loss of the immune capabilities.
3. The determinants of immunoparalysis
Only recently it became clear that the CARS does not represent only a physiologic counterbal-
ance to the inflammatory response to PAMP and DAMP but that it can determine a critical 
condition in and by itself [13, 15].
Actually, different experimental and clinical studies indicate that the advanced stage of sep-
sis and SS is characterized by a reduction of both the innate and adaptive immune responses 
(Table 4). Extensive evidence supports this model, even if large inter-patient differences exist. 
First, monocytes present a reduced expression of membrane HLA-DR in association to either a 
decreased secretion of inflammatory mediators when stimulated or a diminished antigen pre-
sentation. Second, different membrane-bound receptors able to potentiate the immune response, 
including IL-2α, IL-7R α, CD86, etc., are reduced. Third, the production of immunosuppressant 
substances, such and programmed death 1 (PD1) and its ligand (PD-L1), is increased in antigen-
presenting cells, thus inhibiting the activation of T lymphocytes. Fourth, there is an increased 
appearance of immunosuppressive T-cell subpopulations, such as myeloid-derived suppressor 
cell and CD4+ and CD25+ T-regulatory cells (Treg), which suppress adaptive immunity. These appear to be particularly relevant, as Treg (a) actively produce anti-inflammatory cytokines 
including TGF-β and IL-10, (b) downregulate the secretion of pro-inflammatory mediators, (c) 
Factors involved Marker
Monocyte deactivation ↓ mHLA-DR expression
↓ TNF-α production
Tissue macrophage dysfunction Presently none
Negative regulatory mediators ↑ PD-(L)1 expression
↑ CTL-4, BTLA expression
↑ LAG-3 and TIM-3 expression
Receptors downregulation ↓ IL-7 receptor
Apoptosis ↑ FAS
↓ lymphocytes
Suppression of immune cells ↑ CD-4, CD-25
↑ myeloid-derived suppressor cells
Anti-inflammatory cytokines ↑ IL-10, IL-13, IL-4, IL1 receptor antagonists, TGF-β
↑ IL-10/TNF-α
mHLA-DR, human leukocyte antigen on the monocyte surface; PD-(L1), programmed death ligand; CTLA-4, cytotoxic 
lymphocyte antigen 4; BTLA, B and T lymphocyte attenuator; LAG-3, lymphocyte activation gene 3; TIM-3, T lymphocyte 
immunoglobulin protein 3; sFAS, soluble FAS ligand; TGF-β, transforming growth factor-β.
Table 4. Factors of immunosuppression.
Sepsis6
neutralize cytotoxic T cells, and (d) deactivate the monocytes. Fourth, immune cells present 
an increased apoptosis, and their loss is not replaced enough by the production of new ones. 
Finally, the phagocytosis of apoptotic cells by fixed and circulating macrophages leads to a 
switch of the latter to the M2 phenotype, whose feature is an increased production of the anti-
inflammatory substances IL-10 and IL-1ra. Put briefly, all these mechanisms exert their action 
via relatively few common pathways, which include the increased apoptosis determining the 
reduction of immune cells, the loss of antigen presentation, the blunted response to PAMP, 
and the reduction of energy production caused by the impairment of the glucose metabolism 
(Table 5) [16, 17]. All these reactions are driven by epigenetic changes causing in different time 
frames the activation or deactivation of genes involved in the immune response, and the result-
ing phenotype is an intense inflammatory response or, conversely, an immunoparalysis.
4. The diagnosis of immunoparalysis
The recognition of sepsis-induced immunoparalysis is not straightforward because the clini-
cal manifestations associated with the switch from the hyperinflammatory state to CARS and 
the full-blown depression of the immune capabilities are not so protean as the symptoms of 
SS [18]. Moreover, the SSC guidelines focus almost exclusively on the former and pay much 
less attention, if any, to the latter. From a practical and clinical point view, some issues appear 
particularly relevant.
4.1. Timing of onset
The transition from the hyperinflammatory phase to immunoparalysis can be challenging to 
identify and to monitor at the bedside and represents a kind of no man’s land in the clinical 
course of patients which survived from the initial phase of SS.
The onset is highly variable. Actually, although the secretion of immunomodulatory sub-
stances can occur relatively early, their clinical consequences present wide variations. Some 
authors [19] observed a substantial difference of mHLA-DR starting from 3 to 7 days in a small 
group of surgical septic patients, and other authors demonstrated that significant decrease of 
Mechanisms Effect
Endotoxin tolerance ↑ Anti-inflammatory mediators, ↓ pro-inflammatory mediators
↓ Antigen presentation
Apoptosis ↓ Immune cell number
Immune cell number anergy
Energy failure Immune cell anergy
Apoptosis
Epigenetic regulation ↓ Pro-inflammatory mediators
Table 5. Mechanisms of immunoparalysis.
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the CD14/HLA-DR and of heat-shock proteins (HSP) 70 and 90 was present already within 
24 hours from the onset of sepsis [5]; in both studies, these alterations were more marked in 
patients who developed SS later on. More recently, Morris et al. [20] in association with raised 
percentage of regulatory T cells (Treg) were predictive for infections occurring between 3 and 9 days after ICU admission, and a similar timing has been demonstrated also in another study 
in which the mortally rate of secondary infection was ~14% [17]. On the basis of these find-
ings, it is reasonable to hypothesize that (a) a combination of cellular and soluble factors able 
to blunt the immune response is present since the very initial phase of sepsis; (b) their effects 
on the clinical course, namely, the appearance of secondary infections and/or viral reactiva-
tion, can occur within the initial 10 days from the admission; and (c) these are associated with 
a substantial mortality of patients surviving the initial insult.
4.2. Monitoring of the immune function
In ICU patients, every organ system is monitored to allow a change in the treatment tailored 
on the variation observed. An ideal monitoring system should be accurate, cheap, and not 
labor-intensive, and the information gathered should be readily if not continuously avail-
able. Since it has become clear that the immune system in sepsis undergoes modifications 
not reflected by the commonly measured biological variables such as the arterial pressure, 
the heart rate, the urinary output, etc., different investigations aimed to identify one or 
more markers of changes of its functions whose follow-up could be valuable to modify the 
therapy according to its changes: as an example, the occurrence of immunoparalysis contra-
indicates the administration of steroids whose use is recommended by the SSC guidelines.
Several monitoring systems exploring both legs of the immune response have been developed 
so far, based on the repeated assessments of the cells involved, their response to different 
Function Cell Marker Outcome Lab technique Runaround (h)
Innate 
immunity
Neutrophils ↑ Immature forms Death
Secondary 
infections
FC. Hematology 
analyzer
1.5
Monocytes ↓ HLA-DR Death
Secondary 
infections
FC, IHC, PCR 1.5
Adaptive 
immunity
All lymphocytes Lymphopenia Death
Secondary 
infections
FC. Hematology 
analyzer
0.5
White blood cells NTL Death
Secondary 
infections
FC. Hematology 
analyzer
0.5
Both Lymphocytes Viral reactivation Death PCR 12
FC, flow cytometry; IHC, immunohistochemistry; PCR, polymerase chain reaction; NTL, neutrophil/lymphocyte ratio.
Table 6. Some currently available indicators of immune function.
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challenges, and the measurement of the blood concentrations of soluble mediators involved 
in the different clinical frames [14, 15, 21, 22]. It could be useful to describe separately those 
currently available and those which will be used likely in the next future. Most of the former 
(Table 6) can be obtained cheaply and on a daily basis; among all, the neutrophil-to-lymphocyte 
ratio has been indicated as the less costly and more rapidly available monitoring tool [23, 24]. 
Other advanced, expensive, and not yet widely available monitoring tools take advantage of 
more sophisticated lab techniques (Table 7) requiring lab expertise and financial resources put-
ting them at risk of not being used outside the research center. Another dynamic approach, 
which shares the very same limitations of the previously described advanced techniques, con-
sists in challenging the immune cells with substances able to trigger their activation, including 
LPS, other PAMP, and phytohemoagglutinin; actually, a number of investigators demonstrated 
that a blunted response to the stimulation is associated with an increased rate of severe infec-
tious complications in different patient populations [25–27].
Independently from the systems used, it should be clear that the monitoring of the immune 
response in septic as well in other clinical conditions (a) is based on the time variations of 
a panel of indicators and not on a single one and (b) due to their direct and indirect costs, 
Function Cell Marker Outcome Lab technique Runaround (h)
Innate 
immunity
Monocytes ↓ sCD127 Death, 
secondary 
infections
FC, PCR, IHC, 
ELISA
5
Endotoxin 
tolerance
Not clear Cell culture, 
ELISA, FC, IHC
72
↑ PD-L1 Secondary 
infections
FC, IHC 1.5
IL10/TNF ratio Death ELISA 5
Dendritic cells ↓ Count Death, 
secondary 
infections
FC 1.5
Adaptive 
immunity
All lymphocytes ↑ CTLA 4, BTLA Not clear FC, IHC 1.5
↑ PD Death FC, IHC 1.5
CD 127 Death, 
secondary 
infections
FC, IHC 1.5
T cells Proliferation Death, 
secondary 
infections
MODS
Cell culture + FC 72
Treg ↑ Treg Death FC 1.5
Both Transcriptomic CD 74, CX3CR1 Not clear PCR, microarray 72
FC, flow cytometry; IHC, immunohistochemistry; PCR, polymerase chain reaction; ELISA, enzyme-linked immunosorbent 
assay.
Table 7. Some promising, yet not currently available, markers of immunoparalysis.
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it should be limited to the subjects at risk; as an example, it is worthwhile to monitor the 
immune function in patients undergoing multiple abdominal surgical procedures for suture 
dehiscence but not in another one safely recovering after peritonitis.
4.3. The identification of patients at risk of immunoparalysis
Even with the exclusion of clinical conditions and/or treatments known to cause an immu-
noparalysis (i.e., solid and hematologic cancers, autoimmune disorders), etc., this circum-
stance can occur in virtually all ICU patients; however, different studies identified some 
predisposing factors that should be considered particularly relevant, including septic 
shock, advanced age, health care-associated infections, elevated Charlson’s score indicat-
ing a substantial underlying fragility, comorbidities, prolonged hospital and ICU length 
of stay, and multiple surgical procedures [17, 28, 29]. The latter, which are associated with 
the repeated activation of the inflammatory and anti-inflammatory responses, according 
to the multiple hits model, ultimately lead to the exhaustion of the immune response [30] 
(Figure 2).
5. The treatment of immunoparalysis
In the last decade, a number of drugs have been developed to restore a normal immune 
function in patients with solid or hematologic tumors on the basis of many investigations 
Figure 2. The multiple hits phenomenon ultimately leading to the exhaustion of the immune response.
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demonstrating the tumor cells are able to suppress in many different ways the host’s immune 
response against themselves. Independently from the substance use and the molecular target, 
these innovative treatments have been demonstrated to be effective but somehow difficult to 
handle, as they are associated with a number of side effects ranging from mild to life-threat-
ening [31]. As several similarities exist between tumor- and sepsis-induced blunting of the 
immune response [32], it is likely that in the next future the immune-boosting treatments will 
be developed to treat the latter, aiming to develop a precision medicine also in ICU patients 
[33] (Table 8).
Presently, according to the SSC guidelines [2], the immune-targeted approaches are limited to 
the administration of steroids in not fluid and catecholamine-responding SS, whereas the use 
of intravenous immunoglobulins (IvIg) is discouraged. Actually, this latter position is ques-
tionable as a number of trials performed in several thousands of patients demonstrated that 
(a) the administration of IvIg is associated with the reduction of mortality in different subsets 
of SS patients; (b) among the different preparations available, the only ones containing supra-
normal concentrations of IgM and IgA appears more effective, and (c) the improvement of 
survival is time-dependent, as a ~6% increase of mortality has been observed for every day of 
delay in the administration [34].
Besides steroids and IvIg, other treatments aimed to modulate the immune response include 
blood purification (BPT) techniques and a number of substances able to boost it.
Cells/factors involved Alterations Possible therapies
Myeloid cells ↑ Immature neutrophils
↑ Tolerant dendritic cells
↑ Myeloid-derived suppressor cells
↓ Monocyte HLA-DR expression
GM-CSF
Toll-like receptor antagonists
FTL3L
TNF
Lymphocytes ↓ Cytokine production
Altered metabolism
↓ Proliferation
↑ Immune checkpoint inhibitors
Malfunction of NKT cells
↑ Treg and Breg cells
↑ CD 155 expression
Anti-PD1 ab
Anti-PDL 1 ab
Anti CTLA4, TIM3, LAG3 ab
↑ Systemic cytokine release ↑ IL-10
↑ PGE 2
↑ TGFβ
GM-CSF
TLR agonists
FT3L
TNF
GMC-SF, granulocyte-macrophage colony-stimulating factor; FTL3L, FMS-related tyrosine kinase 3 ligand; PD, 
programmed death; PDL1, programmed cell death ligand 1; CTL4, cytotoxic T-cell protein 4; TIM3, T-cell immunoglobulin 
mucin receptor 3; Treg Breg, regulatory T and B cells; TGFβ, transforming growth factor-β; PGE, prostaglandin E2.
Table 8. Immunosuppressive pathways shared by cancer and sepsis.
Immunoparalysis in Septic Shock Patients 11
5.1. Blood purification techniques
Since the 1980s, a number of extracorporeal techniques have been developed aiming to 
remove the “toxic” mediators responsible for the clinical manifestations of SS.
Independently from their principle of functioning (see later), the BPT consists in an extracor-
poreal circuit where the patient’s blood flows till enters in the depurative device; once the 
latter is passed, the blood returns to the patient. According to the principle used, the BPT can 
be subdivided into (a) blood processing or (b) plasma processing techniques. In the former, 
the whole blood is depurated via a number techniques, which differ in terms of type and 
surface of the membranes used, their permeability to the high molecular weight of the septic 
mediators, etc., whereas in the latter the plasma is separated from the blood, processed in a 
cartridge, and reinfused downstream. The mediators can be eliminated through the mem-
branes or adsorbed over it. In both cases, the neutralizing capabilities are time-limited. A 
detailed description of the BPT is beyond the aim of this chapter, but some considerations 
are necessary. First, there are no studies clearly demonstrating the superiority of one of them, 
even if some meta-analysis indicates that the those using the adsorption are more effective; (b) 
they can remove also antibiotics, nutrients, vitamins, hormones, etc.; (c) they require antico-
agulation; and, most importantly; and (d) they are not selective and thus remove pro- as well 
as anti-inflammatory mediators [35].
5.2. Immune-boosting agents
Different substances have been used or likely will be used in the next future (Table 9) to 
enhance the depressed immune function in septic and non-septic critically ill patients, includ-
ing [36, 37]:
• Interferon-γ (IFN-γ) is a cytokine produced by helper T cell and an activator of monocytes. 
Different case series and case report performed in a limited number of patients demon-
strated that its administration was associated with an increased HLA-DR expression; how-
ever, presently there are no RCT fulfilling the EBM criteria demonstrating a beneficial effect 
on the outcome of patients with SS.
• Granulocyte-macrophage colony-stimulating factor (GMC-SF) stimulates the production 
of neutrophils from the bone marrow. Even if prophylactic use in neutropenic patients 
did not demonstrate any beneficial effect, a number of investigations demonstrated that 
its administration was associated with an improved outcome especially in patients with a 
decreased HLA-DR expression.
• Interleukin-7 (IL-7) is a cytokine released by bone marrow and thymus cells that prompts 
the growth and the differentiation of T cells. This substance is considered an immune-
boosting agent in patients with cancer and multifocal leukoencephalopathy and in septic 
patients suffering from immunoparalysis.
• Programmed death inhibitors (PD1i) are proteins whose effect is to block the programmed 
death of immune cells, which appears to be a critical factor for the progression of cancer. 
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This approach is new as it is aims to increase the immune response to the cancer cells 
without interfering with their metabolism. Due to their mechanism of action, their admin-
istration could determine a potentially life-threatening inflammatory reaction caused by 
the sudden release of mediators determining a “cytokine storm”; although their use is not 
codified yet in critically ill septic patients, in a recent RCT, the restoration of the immune 
response in the absence of a hyperinflammatory reaction was demonstrated in some SS 
patients given a novel PD1i at different doses [38].
6. Conclusions
Independently from its source, septic shock can be considered a double-step process: the 
initial phase is characterized by an intense inflammatory response that is counterbalanced 
Treatment Effect Pro Against
Available IvIg Antibacterial action
↓ TNF and other pro-
inflammatory mediators
Many small RCT 
demonstrated their 
efficacy
No EBM-validated 
Heterogeneity of patients 
treated
High costs
Blood purification 
techniques
Removal of mediators Many small RCT 
demonstrated their 
efficacy
Not selective
Heterogeneity of techniques
(i.e., HVHV vs. plasma 
adsorption)
Heterogeneity of patients 
treated
Need of anticoagulation
Not selective
Not yet 
available
Interferon-γ Enhanced production 
of pro-inflammatory 
mediators
Some small RCT 
and case reports 
demonstrated its 
efficacy
Possible septic shock-like
Systemic inflammatory 
reactions
GMC-SF Enhanced production of 
immune cells
” Possible septic shock-like
Systemic inflammatory 
reactions
IL-7 Enhanced production 
of pro-inflammatory 
mediators
” Possible septic shock-like
Systemic inflammatory 
reactions
Immune 
checkpoint 
inhibitors
Reduced apoptosis ” Potentially severe and life-
threatening side effects
High costs
No RCT available
Table 9. Possible immunomodulating treatments in septic shock.
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by the production of several anti-inflammatory substances aiming to restore the immunity 
pre-sepsis steady state. However, in many cases this compensatory mechanism prevails and 
not only extinguishes the initial response but determines a condition of immunoparalysis 
that dominates the clinical course and influences the outcome. Unfortunately, the current 
approach is mainly directed against the initial inflammatory phase although some techniques 
of monitoring of the immune function are currently developed and others are being studied. 
The same concepts apply to treatments directed to potentiate the immune capabilities, but in 
this case the goal appears to be still far.
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